Advantame vs Olestra: which is worse?

What is Advantame?

Advantame is the newest FDA-approved synthetic sweetener, approved in 2014. Like neotame, it is a structural derivative of aspartame but with a vanillin-derived substituent. It is approximately 20,000 times sweeter than sucrose — the most potent sweetener currently approved for food use in the US.

What is Olestra?

Olestra (brand name Olean) is a synthetic fat substitute made from sucrose and fatty acids. Unlike regular fats, olestra is not absorbed by the digestive system — it passes through the body unchanged, providing zero calories while mimicking fat's texture and taste in food. It was developed by Procter & Gamble and FDA-approved in 1996.

Documented risks

Advantame: Advantame is the newest approved high-intensity sweetener with the least post-approval safety data. The FDA approval was based on extensive pre-market animal studies showing no significant toxicity, carcinogenicity, reproductive toxicity, or neurotoxicity at relevant doses. EFSA approved it for EU use in 2014, finding no safety concerns based on the submitted data. Like other synthetic sweeteners, advantame has not been studied for long-term effects in large human populations post-approval. The same gut microbiome and glucose tolerance concerns raised for other sweeteners (aspartame, sucralose, acesulfame K) have not been specifically studied for advantame, though the class-wide concerns are relevant. Given its 2014 approval date, independent long-term safety studies are still limited.

Olestra: Olestra caused significant gastrointestinal side effects that were prominently noted on mandatory warning labels: 'This Product Contains Olestra. Olestra may cause abdominal cramping and loose stools. Olestra inhibits the absorption of some vitamins and other nutrients. Vitamins A, D, E, and K have been added.' Reported gastrointestinal effects included diarrhea, abdominal cramping, oily anal leakage ('anal leakage' or 'rectal leakage'), and fatty stools. These effects were often embarrassing and uncomfortable. Multiple consumer complaints documented GI distress from Olean chips. Beyond GI effects, olestra significantly inhibits the absorption of fat-soluble vitamins (A, D, E, K) and fat-soluble carotenoids (lycopene, lutein, beta-carotene). Since fat-soluble vitamins require fat for absorption, and olestra passes through without being absorbed, it 'captures' these vitamins and carries them out of the body. Studies found olestra consumption reduced serum carotenoid levels, prompting Frito-Lay to fortify olestra products with fat-soluble vitamins to compensate. The FDA removed the mandatory GI warning requirement in 2003 after Frito-Lay argued the warning was overstated, though olestra's use had already declined dramatically due to consumer avoidance.